UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
_________________
Date of Report (Date of earliest event reported): January 28, 2016
Alliqua BioMedical, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware | | 001-36278 | | 58-2349413 |
(State or other jurisdiction
of incorporation) | | (Commission File Number) | | (IRS Employer
Identification No.) |
| | | |
2150 Cabot Boulevard West Langhorne, Pennsylvania | | 19047 |
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (215) 702-8550
| (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c) |
On January 28, 2016, Alliqua BioMedical, Inc. (the “Company”) issued a press release announcing that following the completion of Human Longevity, Inc.’s (“HLI”) planned purchase of LifebankUSA and other select assets from Celgene Cellular Therapeutics (“CCT”), the Company will remain the exclusive commercial partner for the existing pipeline of human placental based products, including Biovance® Human Amniotic Membrane Allograft and CCT’s connective tissue matrix product, which is pending commercial launch under its branded name, Interfyl™ Human Connective Tissue Matrix. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
| Exhibit Number | | Description |
| 99.1 | | Press release dated January 28, 2016. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | ALLIQUA BIOMEDICAL, INC. |
| | | |
| Dated: January 28, 2016 | By: | /s/ Brian Posner |
| | | Name: Brian Posner |
| | | Title: Chief Financial Officer |
